Impact of tranexamic acid on outcomes in early-admitted patients with aneurysmal subarachnoid hemorrhage: a systematic review and bayesian meta-analysis of randomized controlled trials.

Tranexamic acid (tranexamic acid), an antifibrinolytic agent, has been proposed to reduce the risk of rebleeding; however, its impact on outcomes in patients admitted early (≤ 72 h) remains unclear.

Notably, the long-term tranexamic acid protocol subgroup showed a significant increase in cerebral ischemia events (RR 1.68; 95% CrI 1.13 to 2.51), while the short-term protocol did not yield a significant increase (96.3% probability of subgroup difference).